Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

MEFHISTO Decoding and targeting the PGE2-MEF2A axis in tumor-associated macrophages

Coordinator
Universita Vita-Salute San Raffaele, Italy
Runs
1 September 2023 to 31 August 2028
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101088887

What the project is doing

In the project's own words, from its summary on CORDIS.

Inflammation is a complex spectrum of processes whose outcomes range from cell killing to tissue regeneration. In this context, a major goal in immune oncology is the development of treatments that stimulate cytotoxic immunity while limiting repair in the tumor microenvironment (TME), as these approaches have the potential to synergize with available immunotherapies and provide benefit to otherwise resistant patients.

Pancreatic cancer is a largely incurable disease, in which aberrant inflammation and profound immune suppression conspire to sustain disease initiation, progression, and immune escape. Accumulating evidence supports the view that tumor-associated macrophages (TAMs) are key orchestrators of the balance between cytotoxicity and regeneration, and thus represent promising therapeutic targets in pancreatic cancer. In MEFHISTO, we aim at elucidating the molecular control, the functional implications, and the therapeutic potential of the PGE2-MEF2A axis, a newly described pathway enabling selective control of inflammatory gene expression in macrophages.

By combining advanced genomic analyses in human samples, functional experiments in preclinical models, and mechanistic studies in key cell types, this Proposal will expand our knowledge of the organizing principles of innate immune responses in tumors. The ensuing results may lead to novel combinatorial treatments for diseases, such as pancreatic cancer, that are refractory to immunotherapy.

Topics

Who is involved

OrganisationCityCountryRole
Universita Vita-Salute San RaffaeleMilanoItalyCoordinator
Ospedale San Raffaele SRLMilanoItalyThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI